We are proud to announce the approval from the French National Agency for Medicines and Health Products (ANSM Agence nationale de sécurité du médicament et des produits de santé) for the Phase 2 clinical trial EXLIBRIS in collaboration with CHU de Lille to evaluate our lead candidate EXL01 in combination with Nivolumab (anti-PD1) for the treatment of refractory patients with advanced non small cell lung cancer.

Exeliom is excited to embark on this groundbreaking journey, made possible by the dedication of both teams at CHU de Lille and Exeliom Biosciences.

We thank Dr. Alexis Cortot, principal investigator and professor at the department of thoracic oncology at CHU Lille.

The upcoming trial holds immense promise as we aim to explore the potential of EXLIBRIS as a treatment for Lung Cancer.

Stay tuned as we gear up to initiate this pivotal trial in the coming weeks!